San Diego, USA — May 24, 2024. Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announces the completion of a global collaboration agreement with the Shanghai Model Organisms Center (SMOC). This five-year agreement extends the existing partnership and will provide unique immuno-oncology platforms and services from all Crown Bioscience facilities worldwide.
- The purchase and supply of a broad range of genetically engineered mouse models, including thousands of knock-in and knock-out humanized models,
- Custom development of GEMM models and MuPrimeTM (Crown Bioscience’s tumor homograft models) leveraging SMOC-engineered mice.
Globally, Crown Bioscience research affiliates will benefit from uniform pricing, comprehensive IP protection, and licensing rights. This uniformity is accompanied by a shared commitment to research excellence, unrivaled quality standards, and scientific innovation.
- Unprecedented Access: Immediate access to SMOC’s extensive library, featuring over 6,000 off-the-shelf mouse models and more than 11,000 established genetically engineered mouse prototypes.
- Consistent Supply Chain: A reliable source of genetically engineered cell lines and murine models, alongside highly translational humanized models.
- Global Strategic Synergy: Fostering a global strategic partnership, extending beyond procurement, that enhances both entities' capabilities and offerings.
Through this collaboration, Crown Bioscience and SMOC will help bridge the gap between scientific discovery and clinical application and foster the continuous growth and evolution of global research initiatives.
Click here for more information on our innovative immuno-oncology platforms and services.
Contact details
-
- Sarah Martin-Tyrrell
-
JSR Life Sciences Company Inquiries
Senior Manager, PR and Content - sarah.martin-tyrrell@crownbio.com
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Related topics
Related news
Crown Bioscience Completes Merger with Indivumed Services
Crown Bioscience completes Indivumed Services merger, offering enhanced drug development solutions globally and retiring the Indivumed brand.
Crown Bioscience Germany GmbH Achieves Continued CAP 15189:2022 Accreditation
Crown Bioscience's Hamburg site secures continued CAP ISO 15189:2022 accreditation, showcasing its commitment to quality in laboratory services.
Crown Bioscience Wins 2024 Fierce CRO Award for Excellence in Client Service and Partnership
Crown Bioscience wins 2024 Fierce CRO Award for excellence in client service, underscoring its commitment to innovative drug development partnerships.
Crown Bioscience Wins BioTech Breakthrough Award for Drug Development Innovation
Crown Bioscience's OrganoidXplore receives BioTech Award, revolutionizing oncology with advanced preclinical screening.
Prostate Cancer Breakthrough: Crown Bioscience Collaborates in €1.75M Eurostars Funded Project for Novel Liquid Biops...
Crown Bioscience, part of JSR Life Sciences, joins a €1.75M Eurostars project to develop a novel liquid biopsy for prostate cancer, enhancing treatment.